Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia

被引：28

作者：

Khan, Niloufer ^{[1
,2
]}

Hantel, Andrew ^{[3
]}

Knoebel, Randall W. ^{[4
]}

Artz, Andrew ^{[3
]}

Larson, Richard A. ^{[3
]}

Godley, Lucy A. ^{[3
]}

Thirman, Michael J. ^{[3
]}

Liu, Hongtao ^{[3
]}

Churpek, Jane E. ^{[3
]}

King, Darren ^{[5
]}

Odenike, Olatoyosi ^{[3
]}

Stock, Wendy ^{[3
]}

机构：

[1] Univ Chicago Med, Dept Med, Chicago, IL USA

[2] Univ Chicago Med, Dept Pediat, Chicago, IL USA

[3] Univ Chicago Med, Hematol Oncol Sect, Dept Med, Chicago, IL 60637 USA

[4] Univ Chicago Med, Dept Pharm, Chicago, IL USA

[5] Univ Michigan, Dept Med, Sect Hematol Oncol, Ann Arbor, MI 48109 USA

来源：

LEUKEMIA & LYMPHOMA | 2017年 / 58卷 / 09期

关键词：

Decitabine; AML; acute myeloid leukemia; relapsed AML; refractory AML; STEM-CELL TRANSPLANTATION; MYELODYSPLASTIC SYNDROMES; OLDER PATIENTS; PHASE-II; INDUCTION CHEMOTHERAPY; 1ST-LINE TREATMENT; DOSE CYTARABINE; THERAPY; MULTICENTER; TRIAL;

D O I：

10.1080/10428194.2017.1289524

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Improving therapy for relapsed/refractory AML remains a challenge. We performed a retrospective analysis of outcomes following decitabine treatment in 34 patients with relapsed/refractory AML (median age, 62; median Charlson comorbidity score, 6). Decitabine, 20mg/m(2) daily, was given in 5- (25%) or 10-day (75%) cycles. Overall response rate (OR) was 30% with 21% complete remission and 9% partial remission rate. Patients with therapy-related myeloid neoplasm (t-MN) and secondary AML had a significantly higher OR compared to those with de novo AML (70 vs. 30%; p=.02). Median overall survival of all patients was 8.5 months. Median survival in patients with t-MN or secondary AML was 12.4 months compared to 8 months in those with de novo AML (p=.20). Fifteen (44%) patients proceeded to hematopoietic stem cell transplant. These data support using 10-day treatment cycles of decitabine in patients with relapsed/refractory AML, particularly for those with secondary or therapy-related AML.

引用

页码：2127 / 2133

页数：7

共 32 条

[1] Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation
Blum, Kristie A.
Liu, Zhongfa
Lucas, David M.
Chen, Ping
Xie, Zhiliang
Baiocchi, Robert
Benson, Donald M.
Devine, Steven M.
Jones, Jeffrey
Andritsos, Leslie
Flynn, Joseph
Plass, Christoph
Marcucci, Guido
Chan, Kenneth K.
Grever, Michael R.
Byrd, John C.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (02) : 189 - 195
[2] Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
Blum, William
Garzon, Ramiro
Klisovic, Rebecca B.
Schwind, Sebastian
Walker, Alison
Geyer, Susan
Liu, Shujun
Havelange, Violaine
Becker, Heiko
Schaaf, Larry
Mickle, Jon
Devine, Hollie
Kefauver, Cheryl
Devine, Steven M.
Chan, Kenneth K.
Heerema, Nyla A.
Bloomfield, Clara D.
Grever, Michael R.
Byrd, John C.
Villalona-Calero, Miguel
Croce, Carlo M.
Marcucci, Guido
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (16) : 7473 - 7478
[3] Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
Cashen, Amanda F.
Schiller, Gary J.
O'Donnell, Margaret R.
DiPersio, John F.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) : 556 - 561
[4] Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies
Damaj, Gandhi
Duhamel, Alain
Robin, Marie
Beguin, Yves
Michallet, Mauricette
Mohty, Mohamad
Vigouroux, Stephane
Bories, Pierre
Garnier, Alice
El Cheikh, Jean
Bulabois, Claude-Eric
Huynh, Anne
Bay, Jacques-Olivier
Legrand, Faeyzeh
Deconinck, Eric
Fegueux, Nathalie
Clement, Laurence
Dauriac, Charles
Maillard, Natacha
Cornillon, Jerome
Ades, Lionel
Guillerm, Gaelle
Schmidt-Tanguy, Aline
Marjanovic, Zora
Park, Sophie
Rubio, Marie-Therese
Marolleau, Jean-Pierre
Garnier, Federico
Fenaux, Pierre
Yakoub-Agha, Ibrahim
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (36) : 4533 - 4540
[5] Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Doehner, Hartmut
Estey, Elihu H.
Amadori, Sergio
Appelbaum, Frederick R.
Buechner, Thomas
Burnett, Alan K.
Dombret, Herve
Fenaux, Pierre
Grimwade, David
Larson, Richard A.
Lo-Coco, Francesco
Naoe, Tomoki
Niederwieser, Dietger
Ossenkoppele, Gert J.
Sanz, Miguel A.
Sierra, Jorge
Tallman, Martin S.
Loewenberg, Bob
Bloomfield, Clara D.
[J]. BLOOD, 2010, 115 (03) : 453 - 474
[6] Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure
Duval, Michel
Klein, John P.
He, Wensheng
Cahn, Jean-Yves
Cairo, Mitchell
Camitta, Bruce M.
Kamble, Rammurti
Copelan, Edward
de Lima, Marcos
Gupta, Vikas
Keating, Armand
Lazarus, Hillard M.
Litzow, Mark R.
Marks, David I.
Maziarz, Richard T.
Rizzieri, David A.
Schiller, Gary
Schultz, Kirk R.
Tallman, Martin S.
Weisdorf, Daniel
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (23) : 3730 - 3738
[7] FDA, 2013, BACKGROUNDER FDAS HI
[8] A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia
Griffiths, Elizabeth A.
Brady, William E.
Tan, Wei
Vigil, Carlos E.
Thompson, James E.
Ford, Laurie A.
Dickey, Noelle M.
Bashaw, Heather L.
Sperrazza, Jill
Wetzler, Meir
Wang, Eunice S.
[J]. LEUKEMIA RESEARCH, 2016, 43 : 44 - 48
[9] Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients 60 years old
Gupta, Neha
Miller, Austin
Gandhi, Shipra
Ford, Laurie A.
Vigil, Carlos E.
Griffiths, Elizabeth A.
Thompson, James E.
Wetzler, Meir
Wang, Eunice S.
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (07) : 639 - 646
[10] HIGH-DOSE CYTOSINE-ARABINOSIDE THERAPY WITH AND WITHOUT ANTHRACYCLINE ANTIBIOTICS FOR REMISSION REINDUCTION OF ACUTE NONLYMPHOBLASTIC LEUKEMIA
HERZIG, RH
LAZARUS, HM
WOLFF, SN
PHILLIPS, GL
HERZIG, GP
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (07) : 992 - 997

← 1 2 3 4 →